
Atypical Hemolytic Uremic Syndrome (aHUS) - Pipeline Insight, 2025
Description
DelveInsight’s, “Atypical Hemolytic Uremic Syndrome (aHUS) - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Atypical Hemolytic Uremic Syndrome (aHUS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Atypical Hemolytic Uremic Syndrome (aHUS): Overview
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that affects multiple organs and the kidneys in particular. aHUS can be sporadic or familial and is most commonly caused by dysregulation of the alternative complement pathway. The initial attack of aHUS can occur at any age, and is associated with a high rate of progression to end stage renal disease. The majority of aHUS is caused by complement system defects impairing ordinary regulatory mechanisms. Activating events therefore lead to unbridled, ongoing complement activity producing widespread endothelial injury. Pathologic mutations include those resulting in loss-of-function in a complement regulatory gene (CFH, CFI, CD46 or THBD) or gain-of-function in an effector gene (CFB or C3). Treatment with the late complement inhibitor, eculizumab – a monoclonal antibody directed against C5 – is effective.
""Atypical Hemolytic Uremic Syndrome (aHUS) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Hemolytic Uremic Syndrome (aHUS) pipeline landscape is provided which includes the disease overview and Atypical Hemolytic Uremic Syndrome (aHUS) treatment guidelines. The assessment part of the report embraces, in depth Atypical Hemolytic Uremic Syndrome (aHUS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Atypical Hemolytic Uremic Syndrome (aHUS) Emerging Drugs
Further product details are provided in the report……..
Atypical Hemolytic Uremic Syndrome (aHUS): Therapeutic Assessment
This segment of the report provides insights about the different Atypical Hemolytic Uremic Syndrome (aHUS) drugs segregated based on following parameters that define the scope of the report, such as:
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Atypical Hemolytic Uremic Syndrome (aHUS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atypical Hemolytic Uremic Syndrome (aHUS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Hemolytic Uremic Syndrome (aHUS) drugs.
Atypical Hemolytic Uremic Syndrome (aHUS) Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Atypical Hemolytic Uremic Syndrome (aHUS): Overview
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that affects multiple organs and the kidneys in particular. aHUS can be sporadic or familial and is most commonly caused by dysregulation of the alternative complement pathway. The initial attack of aHUS can occur at any age, and is associated with a high rate of progression to end stage renal disease. The majority of aHUS is caused by complement system defects impairing ordinary regulatory mechanisms. Activating events therefore lead to unbridled, ongoing complement activity producing widespread endothelial injury. Pathologic mutations include those resulting in loss-of-function in a complement regulatory gene (CFH, CFI, CD46 or THBD) or gain-of-function in an effector gene (CFB or C3). Treatment with the late complement inhibitor, eculizumab – a monoclonal antibody directed against C5 – is effective.
""Atypical Hemolytic Uremic Syndrome (aHUS) - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Atypical Hemolytic Uremic Syndrome (aHUS) pipeline landscape is provided which includes the disease overview and Atypical Hemolytic Uremic Syndrome (aHUS) treatment guidelines. The assessment part of the report embraces, in depth Atypical Hemolytic Uremic Syndrome (aHUS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence in Atypical Hemolytic Uremic Syndrome (aHUS) R&D. The therapies under development are focused on novel approaches to treat/improve in Atypical Hemolytic Uremic Syndrome (aHUS).
Atypical Hemolytic Uremic Syndrome (aHUS) Emerging Drugs
- Iptacopan: Novartis Pharmaceuticals
Further product details are provided in the report……..
Atypical Hemolytic Uremic Syndrome (aHUS): Therapeutic Assessment
This segment of the report provides insights about the different Atypical Hemolytic Uremic Syndrome (aHUS) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Atypical Hemolytic Uremic Syndrome (aHUS)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Atypical Hemolytic Uremic Syndrome (aHUS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Atypical Hemolytic Uremic Syndrome (aHUS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Atypical Hemolytic Uremic Syndrome (aHUS) drugs.
Atypical Hemolytic Uremic Syndrome (aHUS) Report Insights
- Atypical Hemolytic Uremic Syndrome (aHUS) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Atypical Hemolytic Uremic Syndrome (aHUS) drugs?
- How many Atypical Hemolytic Uremic Syndrome (aHUS) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Atypical Hemolytic Uremic Syndrome (aHUS)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Atypical Hemolytic Uremic Syndrome (aHUS)?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Atypical Hemolytic Uremic Syndrome (aHUS) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis Pharmaceuticals
- Chugai Pharmaceutical
- Tasly Biopharmaceuticals
- Prestige BioPharma
- Iptacopan
- Crovalimab
- B 2067 2
- Eculizumab
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Atypical Hemolytic Uremic Syndrome (aHUS) : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Atypical Hemolytic Uremic Syndrome (aHUS) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Iptacopan: Novartis Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Eculizumab biosimilar: Prestige BioPharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Comparative Analysis
- B 2067 2: Tasly Biopharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Atypical Hemolytic Uremic Syndrome (aHUS) Key Companies
- Atypical Hemolytic Uremic Syndrome (aHUS) Key Products
- Atypical Hemolytic Uremic Syndrome (aHUS) - Unmet Needs
- Atypical Hemolytic Uremic Syndrome (aHUS) - Market Drivers and Barriers
- Atypical Hemolytic Uremic Syndrome (aHUS) - Future Perspectives and Conclusion
- Atypical Hemolytic Uremic Syndrome (aHUS) Analyst Views
- Atypical Hemolytic Uremic Syndrome (aHUS) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.